Biogen’s Post

Increasing numbers of IPF studies and a limited pipeline of participants mean researchers need novel strategies for drug development. Learn how to navigate the changing landscape of research on this rare disease in this blog from our experts. https://ow.ly/VVtR50SwIri

📢 On Rare Disease Day, we support those affected by rare diseases. We're here to help biopharma partners bring innovative therapies to vulnerable patients and their families. Join us in raising awareness and making a difference! Read our article "Nine Questions about Rare and Orphan Drug Commercialization" for insights on navigating this complex field: https://ow.ly/KXiZ50QIKRX. Together, let's drive innovation and improve lives. 💙 #RareDiseaseDay

𝗘𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲 𝗦𝗽𝗲𝗮𝗸𝗲𝗿 𝗜𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄𝘀 Amit Sharma and Samvel Gasparyan discussed the transformations in the kidney disease treatment landscape over the past year, emphasizing notable breakthroughs and persistent obstacles faced by the #CKD field. You can read the full interviews here: https://ter.li/media-hub Join Amit and Samvel, alongside 200+ biopharma stakeholders, KOLs and regulators at the definitive 𝟲𝘁𝗵 𝗖𝗞𝗗 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗦𝘂𝗺𝗺𝗶𝘁 to collaboratively advance the frontier of more personalized, efficacious therapies for rare and common kidney disease.

ICT Spring 2024 is now live! ☀️ Featuring insights in Decentralised Clinical Trials, Orphan Drug and Rare Disease Trials, and much more! Read here: https://bit.ly/3URlpxX #ClinicalTrials #decentralisedclinicaltrials #rarediseases #orphandrugs #pharmaceuticalindustry

Disease registries are a valuable source of real-world data across the drug development process. In our latest blog, we share some insights from our experiences with building disease registries. https://bit.ly/3QVJdxq #registries #RWD

This great read outlines the role of RWE in clinical development. For geneticists operating in the age of growing multi-omics repositories, RWE presents a platform to fine-tune genotype-phenotype matching. Thanks Tsitsi Monera-Penduka, PhD!

Save the date—there's an upcoming virtual meeting for people living with rare diseases, like scleroderma, to discuss the development of therapeutics. 💻 On December 14, 2023 from 12:00 - 5:00 PM ET, the FDA in collaboration with the Duke-Robert J. Margolis, MD Center for Health Policy will be hosting a virtual public meeting. The purpose of this meeting is "to discuss opportunities for engaging the rare disease patient community. This engagement can help inform the development of therapeutics to treat rare diseases and conditions." For more information about discussion topics, speaker bios, and how to register, visit: https://bit.ly/3ReQlp5 #scleroderma #raredisease #virtualmeeting #sayscleroderma #srfcure

Article | What’s hot in molecular diagnostics and where it’s going Staying informed on the latest trends in molecular-diagnostics is key to staying ahead in the fight against disease. Read our blog to find out what’s hot in molecular-diagnostics, and where we are taking it. https://lnkd.in/dUHXesMb #diagnostics #immunodiagnostics #lifesciences #biopharma

Real-world evidence (RWE) is currently a buzzword in the pharmaceutical industry. Here is an overview of RWE's value throughout the entire product life cycle from Tsitsi Monera-Penduka, PhD ##rwe #realworldevidence #realworlddata

US & #APAC Rare Disease Pharma & #Biotech Leaders: Did an #FDA setback derail your #raredisease therapy development? The European pathway could be your strategic advantage. The #EMA offers: 💚 Alternative pathways: Flexibility in trial design & accelerated assessment for unmet needs. 💚 Valuable insights: Address FDA concerns using EMA feedback. 💚 Early market access: Potentially secure approval & generate data for US payers. Dive into part 2 of our "Don't Sleep on the EU" series: The Global Ambition: Mastering Dual Submission for Rare Disease Therapies. https://lnkd.in/dGSGHCuR 💛 Next week's final article, "Hurdles to Harmonization," explores how to leverage EU success for a triumphant return to the #FDA after experiencing a setback. Stay tuned! #biotech #pharma #globalstrategy #drugdevelopment #clinicaltrials #marketaccess